Artivion Reports Fourth Quarter and Full Year 2023 Financial Results
Fourth Quarter and Recent Business Highlights:
- Achieved revenue of $93.7 million in the fourth quarter of 2023 versus $79.4 million in the fourth quarter of 2022, an increase of 18% on a GAAP basis and 15% on a non-GAAP constant currency basis
- Achieved revenue of $354.0 million for the full year of 2023 versus $313.8 million for the full year of 2022, an increase of 13% on a GAAP basis and 12% on a non-GAAP constant currency basis
- Net loss was ($4.0) million or ($0.10) per fully diluted share and non-GAAP net income was $4.6 million or $0.11 per fully diluted share in the fourth quarter of 2023
- Non-GAAP adjusted EBITDA increased 40% to $15.3 million in the fourth quarter of 2023 compared to $11.0 million in the fourth quarter of 2022. For the full year adjusted EBITDA increased 29.5% to $53.8 million
- Generated $11.4 million of free cash flow for the full year of 2023
- Closed non-dilutive credit agreement for $350.0 million of senior secured, interest-only, credit facilities with 6-year maturities
- Completed enrollment of the AMDS PERSEVERE clinical trial and presented positive results of the full IDE cohort at the STS Annual Meeting demonstrating a significant reduction of all-cause mortality and primary major adverse events (MAEs) at 30-days following AMDS implantation
- Appointed Lance A. Berry as Executive Vice President and Chief Financial Officer
ATLANTA, Feb. 15, 2024 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced financial results for the fourth quarter and full year ended December 31, 2023.
"2023 was a standout year for Artivion as we exceeded our revenue and adjusted EBITDA growth targets and continued to deliver on our mission to enhance our world class, aortic focused company with a highly differentiated product portfolio and global footprint. Revenue growth in the fourth quarter was strong across all four of our product lines and all four geographies, driven by particularly strong performance in On-X with 19% constant currency growth and tissue processing with 18% constant currency growth," said Pat Mackin, Chairman, President, and Chief Executive Officer.
Mr. Mackin added, "In addition to our strong commercial results, we also completed enrollment for our PERSEVERE clinical trial which met every primary endpoint and has set the stage for success with AMDS. Trial data out to 30 days demonstrated a 72% reduction in all-cause mortality and a 52% reduction in the primary composite endpoint of major adverse events, with zero occurrence of distal anastomotic new entry, or DANE, when compared to the current standard of care hemiarch procedure. We continue to work with the FDA toward PMA approval, which we anticipate in the second half of 2025."
Mr. Mackin concluded, "Given our solid financial performance, improved capital structure, ongoing clinical progress and operational achievements in 2023, we enter 2024 with strong momentum and confidence in our ability to deliver profitable growth."
Fourth Quarter 2023 Financial Results
Total revenues for the fourth quarter of 2023 were $93.7 million, an increase of 18% on a GAAP basis and 15% on a non-GAAP constant currency basis, both compared to the fourth quarter of 2022.
Net loss for the fourth quarter of 2023 was ($4.0) million, or ($0.10) per fully diluted common share, compared to net income of $2.2 million, or $0.05 per fully diluted common share for the fourth quarter of 2022. Non-GAAP net income for the fourth quarter of 2023 was $4.6 million, or $0.11 per fully diluted common share, compared to non-GAAP net income of $4.2 million, or $0.10 per fully diluted common share for the fourth quarter of 2022. Non-GAAP net income for the fourth quarter of 2023 includes pretax gains related to foreign currency revaluation of $2.2 million.
Full Year 2023 Financial Results
Total revenues for 2023 were $354.0 million, reflecting an increase of 13% on a GAAP basis and 12% on a non-GAAP constant currency basis compared to the full year of 2022.
Net loss for 2023 was ($30.7) million, or ($0.75) per fully diluted common share, compared to net loss of ($19.2) million, or ($0.48) per fully diluted common share for the full year of 2022. Non-GAAP net income for the full year of 2023 was $8.4 million, or $0.20 per fully diluted common share, compared to non-GAAP net income of $2.1 million, or $0.05 per fully diluted common share for the full year of 2022. Non-GAAP net income for the full year of 2023 includes pretax gains related to foreign currency revaluation of $2.1 million.
2024 Financial Outlook
The Company expects revenues for the full year 2024 to be in the range of $382 to $396 million, representing growth of 8% to 12% compared to 2023 on both an as reported and constant currency basis. At current exchange rates, the company expects negligible year-over-year currency impact to revenue.
Artivion expects non-GAAP adjusted EBITDA, to increase between 26% and 34% for the full year 2024 compared to 2023, resulting in non-GAAP adjusted EBITDA to be in the range of $68 to $72 million in 2024.
The Company's financial performance for 2024 and future periods is subject to the risks identified below.
Non-GAAP Financial Measures
This press release contains non-GAAP financial measures, including non-GAAP revenue, non-GAAP net income, non-GAAP adjusted EBITDA, non-GAAP general, administrative, and marketing expenses, and free cash flows. Investors should consider this non-GAAP information in addition to, and not as a substitute for, financial measures prepared in accordance with US GAAP. In addition, this non-GAAP financial information may not be the same as similar measures presented by other companies. The Company's non-GAAP revenues are adjusted for the impact of changes in currency exchange. The Company's non-GAAP net income; non-GAAP adjusted EBITDA; non-GAAP general, administrative, and marketing, and free cash flows results exclude (as applicable) depreciation and amortization expense; interest income and expense; stock-based compensation expense; loss or gain on foreign currency revaluation; income tax expense or benefit; corporate rebranding expense; business development, integration, and severance income or expense; non-cash interest expense; gain from sale of non-financial assets, and abandonment of CardioGenesis cardiac laser therapy business. The Company generally uses non-GAAP financial measures to facilitate management's review of the operational performance of the company and as a basis for strategic planning. Company management believes that these non-GAAP presentations provide useful information to investors regarding unusual non-operating transactions; the operating expense structure of the Company's existing and recently acquired operations, without regard to its on-going efforts to acquire additional complementary products and businesses, and the transaction and integration expenses incurred in connection with recently acquired and divested product lines; and the operating expense structure excluding fluctuations resulting from foreign currency revaluation and stock-based compensation expense. The Company believes it is useful to exclude certain expenses because such amounts in any specific period may not directly correlate to the underlying performance of its business operations or can vary significantly between periods as a result of factors such as impact of recent acquisitions, non-cash expense related to amortization of previously acquired tangible and intangible assets, and any related adjustments to their carrying values. The Company has adjusted for the impact of changes in currency exchange from certain revenues to evaluate comparable product growth rates on a constant currency basis. The Company does, however, expect to incur similar types of expenses and currency exchange impacts in the future, and this non-GAAP financial information should not be viewed as a statement or indication that these types of expenses will not recur. Company management encourages investors to review the Company's consolidated financial statements and publicly filed reports in their entirety, including the reconciliation of GAAP to non-GAAP financial measures.
Webcast and Conference Call Information
The company will hold a teleconference call and live webcast on February 15, 2024, at 4:30 p.m. ET to discuss the results, followed by a question and answer session. To participate in the conference call dial 201-689-8261 a few minutes prior to 4:30 p.m. ET. The teleconference replay will be available approximately one hour following the completion of the event and can be accessed by calling (toll free) 877-660-6853 or 201-612-7415. The conference number for the replay is 13742847.
The live webcast and replay can be accessed by going to the Investors section of the Artivion website at www.Artivion.com and selecting the heading Webcasts & Presentations.
About Artivion, Inc.
Headquartered in suburban Atlanta, Georgia, Artivion, Inc. is a medical device company focused on developing simple, elegant solutions that address cardiac and vascular surgeons' most difficult challenges in treating patients with aortic diseases. Artivion's four major groups of products include: aortic stent grafts, surgical sealants, On-X mechanical heart valves, and implantable cardiac and vascular human tissues. Artivion markets and sells products in more than 100 countries worldwide. For additional information about Artivion, visit our website, www.Artivion.com.
Forward Looking-Statements
Statements made in this press release that look forward in time or that express management's beliefs, expectations, or hopes are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements reflect the views of management at the time such statements are made. These statements include, but are not limited to, that we are entering 2024 with strong momentum and confidence in our ability to drive profitable growth, given our financial performance in 2023, our improved capital structure, and our on-going clinical progress; we expect revenues for the full year 2024 to be in the range of $382 to $396 million, representing revenue growth of between 8% to 12% compared to 2023, both as reported and on a constant currency basis; expect, at current exchange rates, negligible impact year-over-year to revenue on a constant currency basis; and expect non-GAAP adjusted EBITDA, to increase between 26% and 34% for the full year 2024 compared to 2023, resulting in non-GAAP adjusted EBITDA in the range of $68 to $72 million in 2024. These forward-looking statements are subject to a number of risks, uncertainties, estimates and assumptions that may cause actual results to differ materially from current expectations, including but not limited to the benefits anticipated from the Ascyrus Medical LLC transaction and Endospan agreements and our operational improvements in our tissue business may not be achieved at all or at the levels we anticipate or had originally anticipated; and the benefits anticipated from our clinical trials and regulatory approvals not be achieved or achieved on our anticipated timelines. These risks and uncertainties include the risk factors detailed in our Securities and Exchange Commission filings, including our Form 10-K for the year ended December 31, 2023 and subsequent Quarterly Reports on Form 10-Q and annual reports on Form 10-K. Artivion does not undertake to update its forward-looking statements, whether as a result of new information, future events, or otherwise.
Artivion, Inc. and Subsidiaries Consolidated Statements of Operations and Comprehensive Income (Loss) In Thousands, Except Per Share Data | |||||||
(Unaudited) | |||||||
Three Months Ended | Twelve Months Ended | ||||||
2023 | 2022 | 2023 | 2022 | ||||
Revenues: | |||||||
Products | $ 69,144 | $ 58,627 | $ 261,185 | $ 230,353 | |||
Preservation services | 24,526 | 20,771 | 92,819 | 83,436 | |||
Total revenues | 93,670 | 79,398 | 354,004 | 313,789 | |||
Cost of products and preservation services: | |||||||
Products | 22,511 | 18,785 | 84,595 | 72,166 | |||
Preservation services | 10,064 | 9,725 | 40,233 | 39,100 | |||
Total cost of products and preservation services | 32,575 | 28,510 | 124,828 | 111,266 | |||
Gross margin | 61,095 | 50,888 | 229,176 | 202,523 | |||
Operating expenses: | |||||||
General, administrative, and marketing | 50,278 | 38,454 | 208,977 | 157,443 | |||
Research and development | 7,645 | 8,304 | 28,707 | 38,879 | |||
Total operating expenses | 57,923 | 46,758 | 237,684 | 196,322 | |||
Gain from sale of non-financial assets | — | — | (14,250) | — | |||
Operating income | 3,172 | 4,130 | 5,742 | 6,201 | |||
Interest expense | 6,244 | 5,370 | 25,299 | 18,224 | |||
Interest income | (398) | (61) | (1,077) | (147) | |||
Other (income) expense, net | (2,083) | (4,456) | 3,106 | 3,108 | |||
(Loss) income before income taxes | (591) | 3,277 | (21,586) | (14,984) | |||
Income tax expense | 3,384 | 1,108 | 9,104 | 4,208 | |||
Net (loss) income | $ (3,975) | $ 2,169 | $ (30,690) | $ (19,192) | |||
(Loss) income per share: | |||||||
Basic | $ (0.10) | 0.05 | $ (0.75) | $ (0.48) | |||
Diluted | $ (0.10) | $ 0.05 | $ (0.75) | $ (0.48) | |||
Weighted-average common shares outstanding: | |||||||
Basic | 40,898 | 40,127 | 40,743 | 40,032 | |||
Diluted | 40,898 | 40,509 | 40,743 | 40,032 | |||
Net (loss) income | $ (3,975) | $ 2,169 | $ (30,690) | $ (19,192) | |||
Other comprehensive income (loss): | |||||||
Foreign currency translation adjustments | 9,167 | 23,744 | 9,599 | (11,722) | |||
Comprehensive income (loss) | $ 5,192 | $ 25,913 | $ (21,091) | $ (30,914) | |||
Artivion, Inc. and Subsidiaries Consolidated Balance Sheets In Thousands, Except Per Share Data | |||
December 31, | |||
2023 | 2022 | ||
ASSETS | |||
Current assets: | |||
Cash and cash equivalents | $ 58,940 | $ 39,351 | |
Trade receivables, net | 71,796 | 61,820 | |
Other receivables | 2,342 | 7,764 | |
Inventories, net | 81,976 | 74,478 | |
Deferred preservation costs, net | 49,804 | 46,371 | |
Prepaid expenses and other | 15,810 | 17,550 | |
Total current assets | 280,668 | 247,334 | |
Goodwill | 247,337 | 243,631 | |
Acquired technology, net | 142,593 | 151,263 | |
Operating lease right-of-use assets, net | 43,822 | 41,859 | |
Property and equipment, net | 38,358 | 38,674 | |
Other intangibles, net | 29,638 | 31,384 | |
Deferred income taxes | 1,087 | 1,314 | |
Other long-term assets | 8,894 | 7,339 | |
Total assets | $ 792,397 | $ 762,798 | |
Artivion, Inc. and Subsidiaries Consolidated Balance Sheets In Thousands, Except Per Share Data | |||
December 31, | |||
2023 | 2022 | ||
LIABILITIES AND SHAREHOLDERS' EQUITY | |||
Current liabilities: | |||
Accounts payable | $ 13,318 | $ 12,004 | |
Accrued compensation | 18,715 | 13,810 | |
Accrued expenses | 12,732 | 12,374 | |
Taxes payable | 3,840 | 2,635 | |
Current maturities of operating leases | 3,395 | 3,308 | |
Current portion of long-term debt | 1,451 | 1,608 | |
Accrued procurement fees | 1,439 | 2,111 | |
Current portion of finance lease obligation | 582 | 513 | |
Other | 2,390 | 1,312 | |
Total current liabilities | 57,862 | 49,675 | |
Long-term debt | 305,531 | 306,499 | |
Contingent consideration | 63,890 | 40,400 | |
Non-current maturities of operating leases | 43,977 | 41,257 | |
Deferred income taxes | 21,851 | 24,499 | |
Deferred compensation liability | 6,760 | 5,468 | |
Non-current finance lease obligations | 3,405 | 3,644 | |
Other | 7,341 | 7,027 | |
Total liabilities | 510,617 | 478,469 | |
Commitments and contingencies | |||
Shareholders' equity: | |||
Preferred stock $0.01 par value per share, 5,000 shares authorized, no shares issued | — | — | |
Common stock $0.01 par value per share, 75,000 shares authorized, 42,569 and 41,830 | 426 | 418 | |
Additional paid-in capital | 355,919 | 337,385 | |
Retained deficit | (47,907) | (17,217) | |
Accumulated other comprehensive loss | (12,010) | (21,609) | |
Treasury stock at cost, 1,487 shares as of December 31, 2023 and 2022 | (14,648) | (14,648) | |
Total shareholders' equity | 281,780 | 284,329 | |
Total liabilities and shareholders' equity | $ 792,397 | $ 762,798 | |
Artivion, Inc. and Subsidiaries Consolidated Statement of Cash Flows In Thousands | |||
Year Ended December 31, | |||
2023 | 2022 | ||
Net cash flows from operating activities: | |||
Net loss | $ (30,690) | $ (19,192) | |
Adjustments to reconcile net loss to net cash from operating activities: | |||
Change in fair value of contingent consideration | 23,490 | (9,000) | |
Depreciation and amortization | 23,076 | 22,442 | |
Non-cash compensation | 14,422 | 12,344 | |
Non-cash lease expense | 7,354 | 7,432 | |
Fair value adjustment of long-term loan | 5,000 | — | |
Write-down of inventories and deferred preservation costs | 4,785 | 4,374 | |
Non-cash interest expense | 1,858 | 1,832 | |
Deferred income taxes | (1,385) | (1,717) | |
Gain on sale of non-financial assets | (14,250) | — | |
Other | 1,358 | 2,268 | |
Changes in operating assets and liabilities: | |||
Accounts payable, accrued expenses, and other liabilities | 1,682 | (1,958) | |
Prepaid expenses and other assets | 535 | (2,234) | |
Receivables | (4,050) | (13,340) | |
Inventories and deferred preservation costs | (14,360) | (8,404) | |
Net cash flows provided by (used in) operating activities | 18,825 | (5,153) | |
Net cash flows from investing activities: | |||
Proceeds from sale of non-financial assets, net | 14,250 | — | |
Payments for Endospan agreement | (5,000) | — | |
Capital expenditures | (7,430) | (9,016) | |
Other | (2,322) | (1,699) | |
Net cash flows used in investing activities | (502) | (10,715) | |
Net cash flows from financing activities: | |||
Proceeds from exercise of stock options and issuance of common stock | 3,955 | 3,368 | |
Proceeds from financing insurance premiums | 3,558 | — | |
Payment of debt issuance costs | (249) | — | |
Redemption and repurchase of stock to cover tax withholdings | (559) | (1,795) | |
Principal payments on short-term notes payable | (2,531) | — | |
Repayment of debt | (2,772) | (2,753) | |
Other | (537) | (459) | |
Net cash flows provided by (used in) financing activities | 865 | (1,639) | |
Effect of exchange rate changes on cash and cash equivalents | 401 | 1,848 | |
Increase (decrease) in cash and cash equivalents | 19,589 | (15,659) | |
Cash and cash equivalents, beginning of year | 39,351 | 55,010 | |
Cash and cash equivalents, end of year | $ 58,940 | $ 39,351 | |
Artivion, Inc. and Subsidiaries Financial Highlights In Thousands (Unaudited) | |||||||
Three Months Ended | Twelve Months Ended | ||||||
2023 | 2022 | 2023 | 2022 | ||||
Products: | |||||||
Aortic stent grafts | $ 27,437 | $ 23,739 | $ 107,469 | $ 92,752 | |||
On-X | 20,182 | 16,822 | 74,528 | 63,904 | |||
Surgical sealants | 18,513 | 16,357 | 68,016 | 65,379 | |||
Other | 3,012 | 1,709 | 11,172 | 8,318 | |||
Total products | 69,144 | 58,627 | 261,185 | 230,353 | |||
Preservation services | 24,526 | 20,771 | 92,819 | 83,436 | |||
Total revenues | $ 93,670 | $ 79,398 | $ 354,004 | $ 313,789 | |||
North America | 50,062 | 42,709 | 187,603 | 167,542 | |||
Europe, the Middle East, and Africa | 30,206 | 25,611 | 114,814 | 104,119 | |||
Asia Pacific | 8,922 | 7,481 | 33,577 | 27,973 | |||
Latin America | 4,480 | 3,597 | 18,010 | 14,155 | |||
Total revenues | $ 93,670 | $ 79,398 | $ 354,004 | $ 313,789 | |||
Artivion, Inc. and Subsidiaries Reconciliation of GAAP to Non-GAAP Revenues In Thousands (Unaudited) | |||||||||
Revenues for the | Percent Change From Prior Year | ||||||||
2023 | 2022 | ||||||||
US GAAP | US GAAP | Exchange | Constant | Constant | |||||
Products: | |||||||||
Aortic stent grafts | $ 27,437 | $ 23,739 | $ 1,604 | $ 25,343 | 8 % | ||||
Surgical sealants | 18,513 | 16,357 | 273 | 16,630 | 11 % | ||||
On-X | 20,182 | 16,822 | 189 | 17,011 | 19 % | ||||
Other | 3,012 | 1,709 | 14 | 1,723 | 75 % | ||||
Total products | 69,144 | 58,627 | 2,080 | 60,707 | 14 % | ||||
Preservation services | 24,526 | 20,771 | (7) | 20,764 | 18 % | ||||
Total | $ 93,670 | $ 79,398 | $ 2,073 | $ 81,471 | 15 % | ||||
North America | 50,062 | 42,709 | (15) | 42,694 | 17 % | ||||
Europe, the Middle East, and Africa | 30,206 | 25,611 | 1,907 | 27,518 | 10 % | ||||
Asia Pacific | 8,922 | 7,481 | 6 | 7,487 | 19 % | ||||
Latin America | 4,480 | 3,597 | 175 | 3,772 | 19 % | ||||
Total | $ 93,670 | $ 79,398 | $ 2,073 | $ 81,471 | 15 % | ||||
Revenues for the | Percent Change From Prior Year | ||||||||
2023 | 2022 | ||||||||
US GAAP | US GAAP | Exchange | Constant | Constant | |||||
Products: | |||||||||
Aortic stent grafts | $ 107,469 | $ 92,752 | $ 1,587 | $ 94,339 | 14 % | ||||
Surgical sealants | 68,016 | $ 65,379 | 236 | 65,615 | 4 % | ||||
On-X | 74,528 | $ 63,904 | 61 | 63,965 | 17 % | ||||
Other | 11,172 | $ 8,318 | 4 | 8,322 | 34 % | ||||
Total products | 261,185 | 230,353 | 1,888 | 232,241 | 12 % | ||||
Preservation services | $ 92,819 | $ 83,436 | (88) | 83,348 | 11 % | ||||
Total | $ 354,004 | $ 313,789 | $ 1,800 | $ 315,589 | 12 % | ||||
North America | 187,603 | 167,542 | (268) | 167,274 | 12 % | ||||
Europe, the Middle East, and Africa | 114,814 | 104,119 | 1,787 | 105,906 | 8 % | ||||
Asia Pacific | 33,577 | 27,973 | (73) | 27,900 | 20 % | ||||
Latin America | 18,010 | 14,155 | 354 | 14,509 | 24 % | ||||
Total | $ 354,004 | $ 313,789 | $ 1,800 | $ 315,589 | 12 % | ||||
Artivion, Inc. and Subsidiaries Reconciliation of GAAP to Non-GAAP General, Administrative, and Marketing Expense, Adjusted EBITDA, and Free Cash Flows In Thousands (Unaudited) | |||||||
Three Months Ended | Twelve Months Ended | ||||||
2023 | 2022 | 2023 | 2022 | ||||
Reconciliation of G&A expenses, GAAP to adjusted G&A, non-GAAP: | |||||||
General, administrative, and marketing expense, GAAP | $ 50,278 | $ 38,454 | $ 208,977 | $ 157,443 | |||
Business development, integration, and severance expense (income) | 2,531 | (3,934) | 24,992 | (7,750) | |||
Corporate rebranding expense | 72 | 499 | 355 | 1,908 | |||
Abandonment of CardioGenesis cardiac laser therapy business | — | — | 160 | — | |||
Adjusted G&A, non-GAAP | $ 47,675 | $ 41,889 | $ 183,470 | $ 163,285 | |||
Three Months Ended | Twelve Months Ended | ||||||
2023 | 2022 | 2023 | 2022 | ||||
Reconciliation of net (loss) income, GAAP to adjusted EBITDA, non-GAAP: | |||||||
Net (loss) income, GAAP | $ (3,975) | $ 2,169 | $ (30,690) | $ (19,192) | |||
Adjustments: | |||||||
Business development, integration, and severance expense (income) | 2,425 | (2,036) | 29,269 | (5,852) | |||
Interest expense | 6,244 | 5,370 | 25,299 | 18,224 | |||
Depreciation and amortization expense | 5,816 | 5,426 | 23,076 | 22,442 | |||
Stock-based compensation expense | 3,956 | 3,155 | 14,422 | 12,344 | |||
Income tax expense | 3,384 | 1,108 | 9,104 | 4,208 | |||
Abandonment of CardioGenesis cardiac laser therapy business | — | — | 390 | — | |||
Corporate rebranding expense | 72 | 499 | 355 | 1,908 | |||
Clinical trial termination (income) expense | — | (197) | — | 4,544 | |||
Interest income | (398) | (61) | (1,077) | (147) | |||
(Gain) loss on foreign currency revaluation | (2,192) | (4,470) | (2,080) | 3,085 | |||
Gain from sale of non-financial assets | — | — | (14,250) | — | |||
Adjusted EBITDA, non-GAAP | $ 15,332 | $ 10,963 | $ 53,818 | $ 41,564 | |||
Three Months Ended | Twelve Months Ended | ||||||
2023 | 2022 | 2023 | 2022 | ||||
Reconciliation of cash flows from operating activities, GAAP to free | |||||||
Net cash flows provided by (used in) operating activities | $ 9,299 | $ (217) | $ 18,825 | $ (5,153) | |||
Capital expenditures | (1,927) | (2,092) | (7,430) | (9,016) | |||
Free cash flows, non-GAAP | $ 7,372 | $ (2,309) | $ 11,395 | $ (14,169) | |||
Artivion Inc. and Subsidiaries Reconciliation of GAAP to Non-GAAP Net Income and Diluted Income Per Common Share In Thousands, Except Per Share Data (Unaudited) | |||||||
Three Months Ended | Twelve Months Ended | ||||||
2023 | 2022 | 2023 | 2022 | ||||
GAAP: | |||||||
(Loss) income before income taxes | $ (591) | $ 3,277 | $ (21,586) | $ (14,984) | |||
Income tax expense | 3,384 | 1,108 | 9,104 | 4,208 | |||
Net (loss) income | $ (3,975) | $ 2,169 | $ (30,690) | $ (19,192) | |||
Diluted (loss) income per common share | $ (0.10) | $ 0.05 | $ (0.75) | $ (0.48) | |||
Diluted weighted-average common shares outstanding | 40,898 | 40,509 | 40,743 | 40,032 | |||
Reconciliation of (loss) income before income taxes, GAAP to | |||||||
(Loss) income before income taxes, GAAP: | $ (591) | $ 3,277 | $ (21,586) | $ (14,984) | |||
Adjustments: | |||||||
Business development, integration, and severance expense (income) | 2,425 | (2,036) | 29,269 | (5,852) | |||
Amortization expense | 3,745 | 3,635 | 15,198 | 15,310 | |||
Non-cash interest expense | 467 | 460 | 1,858 | 1,832 | |||
Abandonment of CardioGenesis cardiac laser therapy business | — | — | 390 | — | |||
Corporate rebranding expense | 72 | 499 | 355 | 1,908 | |||
Clinical trial termination (income) expense | — | (197) | — | 4,544 | |||
Gain from sale of non-financial assets | — | — | (14,250) | — | |||
Adjusted income before income taxes, non-GAAP | 6,118 | 5,638 | 11,234 | 2,758 | |||
Income tax expense calculated at a tax rate of 25% | 1,529 | 1,409 | 2,808 | 689 | |||
Adjusted net income, non-GAAP | $ 4,589 | $ 4,229 | $ 8,426 | $ 2,069 | |||
Reconciliation of diluted (loss) income per common share, GAAP to | |||||||
Diluted (loss) income per common share, GAAP: | $ (0.10) | $ 0.05 | $ (0.75) | $ (0.48) | |||
Adjustments: | |||||||
Business development, integration, and severance expense (income) | 0.06 | (0.05) | 0.71 | (0.14) | |||
Amortization expense | 0.09 | 0.09 | 0.37 | 0.38 | |||
Non-cash interest expense | 0.01 | 0.01 | 0.04 | 0.04 | |||
Abandonment of CardioGenesis cardiac laser therapy business | — | — | 0.01 | — | |||
Corporate rebranding expense | — | 0.02 | 0.01 | 0.05 | |||
Clinical trial termination (income) expense | — | (0.01) | — | 0.11 | |||
Tax effect of non-GAAP adjustments | (0.03) | (0.02) | (0.20) | (0.11) | |||
Gain from sale of non-financial assets | — | — | (0.34) | — | |||
Effect of 25% tax rate | 0.08 | 0.01 | 0.35 | 0.20 | |||
Adjusted diluted income per common share, non-GAAP | $ 0.11 | $ 0.10 | $ 0.20 | $ 0.05 | |||
Reconciliation of diluted weighted-average common shares | |||||||
Diluted weighted-average common shares outstanding, GAAP: | 40,898 | 40,509 | 40,743 | 40,032 | |||
Adjustments: | |||||||
Effect of dilutive stock options and awards | 802 | — | 598 | 464 | |||
Diluted weighted-average common shares outstanding, non-GAAP | 41,700 | 40,509 | 41,341 | 40,496 | |||
Contacts: | |
Artivion | Gilmartin Group LLC |
Lance A. Berry | Brian Johnston / Laine Morgan |
Executive Vice President & | Phone: 332-895-3222 |
Chief Financial Officer | |
Phone: 770-419-3355 | |
SOURCE Artivion
Share this article